Conatus Pharmaceuticals' emricasan is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis.

Under an exclusive license agreement with Novartis for emricasan, we conducted a series of EmricasaN, a Caspase inhibitOR, for Evaluation clinical trials, or ENCORE trials, designed to provide efficacy and safety data for emricasan in patients with NASH fibrosis and cirrhosis. These trials failed to meet their primary endpoints.